159 related articles for article (PubMed ID: 36791335)
21. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
[TBL] [Abstract][Full Text] [Related]
22. Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.
Wang L; Collins C; Kelly EJ; Chu X; Ray AS; Salphati L; Xiao G; Lee C; Lai Y; Liao M; Mathias A; Evers R; Humphreys W; Hop CE; Kumer SC; Unadkat JD
Drug Metab Dispos; 2016 Nov; 44(11):1752-1758. PubMed ID: 27543206
[TBL] [Abstract][Full Text] [Related]
23. Ultrasensitive Quantification of Drug-metabolizing Enzymes and Transporters in Small Sample Volume by Microflow LC-MS/MS.
Ahire DS; Basit A; Karasu M; Prasad B
J Pharm Sci; 2021 Jul; 110(7):2833-2840. PubMed ID: 33785352
[TBL] [Abstract][Full Text] [Related]
24. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
25. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
26. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
El-Khateeb E; Achour B; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
Mol Pharm; 2021 Sep; 18(9):3563-3577. PubMed ID: 34428046
[TBL] [Abstract][Full Text] [Related]
27. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
28. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
29. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters.
Li J; Zhu HJ
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545386
[TBL] [Abstract][Full Text] [Related]
30. 5-Fluorouracil treatment alters the expression of intestinal transporters in rats.
Yotsumoto K; Akiyoshi T; Wada N; Imaoka A; Ohtani H
Biopharm Drug Dispos; 2017 Dec; 38(9):509-516. PubMed ID: 28849584
[TBL] [Abstract][Full Text] [Related]
31. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
32. Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.
Couto N; Al-Majdoub ZM; Gibson S; Davies PJ; Achour B; Harwood MD; Carlson G; Barber J; Rostami-Hodjegan A; Warhurst G
Drug Metab Dispos; 2020 Apr; 48(4):245-254. PubMed ID: 31959703
[TBL] [Abstract][Full Text] [Related]
33. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
34. Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics.
Anoshchenko O; Prasad B; Neradugomma NK; Wang J; Mao Q; Unadkat JD
Drug Metab Dispos; 2020 Sep; 48(9):735-741. PubMed ID: 32591415
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
36. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
Kalitsky-Szirtes J; Shayeganpour A; Brocks DR; Piquette-Miller M
Drug Metab Dispos; 2004 Jan; 32(1):20-7. PubMed ID: 14709616
[TBL] [Abstract][Full Text] [Related]
37. Application of Quantitative Targeted Absolute Proteomics to Profile Protein Expression Changes of Hepatic Transporters and Metabolizing Enzymes During Cholic Acid-Promoted Liver Regeneration.
Miura T; Tachikawa M; Ohtsuka H; Fukase K; Nakayama S; Sakata N; Motoi F; Naitoh T; Katayose Y; Uchida Y; Ohtsuki S; Terasaki T; Unno M
J Pharm Sci; 2017 Sep; 106(9):2499-2508. PubMed ID: 28249806
[TBL] [Abstract][Full Text] [Related]
38. The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis.
Harwood MD; Zhang M; Pathak SM; Neuhoff S
Drug Metab Dispos; 2019 Aug; 47(8):854-864. PubMed ID: 31076413
[TBL] [Abstract][Full Text] [Related]
39. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Rodrigues AD; Lai Y; Shen H; Varma MVS; Rowland A; Oswald S
Drug Metab Dispos; 2020 Mar; 48(3):205-216. PubMed ID: 31879282
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
